Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)

Cedrés, S.; Núñez, Isaac; Longo, Marina; Martı́nez, Pablo; Checa, Eva; Torrejon, Davis Y.; Felip, Enriqueta

doi:10.1016/j.cllc.2011.03.019

Cited by 182 publications

(154 citation statements)

References 31 publications

Supporting

Mentioning

143

Contrasting

Unclassified

Order By: Relevance

“…Table II shows that the positive expression rates of CEA in squamous cell carcinoma and adenocarcinoma were 42.9 and 73.3%, respectively. The level of CEA in the EBC and serum of adenocarcinoma patients was higher compared with that of squamous cell carcinoma patients: This finding is consistent with those described in other studies (19,21). This finding also revealed that the level of CEA in the EBC is valuable for the diagnosis of pathological lung cancer types.…”

Section: Discussionsupporting

confidence: 91%

“…This analysis indicated that the levels of CEA in the EBC and serum of patients with lung cancer in stages III and IV were higher compared with those of patients with lung cancer in stages I and II (Table III). The level of CEA is likely to increase as the disease progresses (21), and this pattern revealed that the regular monitoring of EBC CEA may contribute to the assessment of lung cancer development. Regular monitoring may also serve as a guide for clinical treatments (22).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Detection of cancer embryo antigen and endothelin-1 in exhaled breath condensate: A novel approach to investigate non-small cell lung cancer

Chen

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 91%

Section: Discussionmentioning

confidence: 99%

Detection of cancer embryo antigen and endothelin-1 in exhaled breath condensate: A novel approach to investigate non-small cell lung cancer

Chen

et al. 2016

Molecular and Clinical Oncology

View full text Add to dashboard Cite

“…Proteomic analytical techniques (Yanagisawa et al 2003, Hassanein et al 2011 have been used in the study of lung cancer, and this has yielded protein biomarkers that have been demonstrated to have high specificity in a study of 54 individuals diagnosed with NSCLC (Zeng et al 2011). Serologic biomarkers of lung cancer have emerged recently: these include carcinoembryonic antigen, the cytokeratin 19 fragment CYFRA21-1, cancer antigen CA-125 (Cedres et al 2011), plasma kallikrein (Chee et al 2008), progastrin-releasing peptide (ProGRP), and neuron-specific enolase (NSE) (Wojcik et al 2008). However, there are relatively few studies of small molecule serological biomarkers of lung cancer.…”

Section: Introductionmentioning

confidence: 99%

Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients

Ravipati

Baldwin²,

Barr

et al. 2015

Metabolomics

View full text Add to dashboard Cite

There is a clinical need for reliable biomarkers for lung cancer that permit early diagnosis of the disease and provide prediction of histological phenotype. A prospective study design was used with a study population of patients with suspected lung cancer. Blood samples were collected from 17 patients with histologically confirmed squamous cell lung carcinoma, 17 individuals with adenocarcinoma, and 17 control individuals who did not subsequently have a diagnosis of lung cancer or any other cancer. Blood plasma samples were analysed for their lipid profiles using liquid chromatography coupled with high resolution mass spectrometry. Data were analysed using multivariate statistical methods. There was good separation between histological subtypes and control groups and also between individuals with a subsequent diagnosis of adenocarcinoma and squamous cell carcinoma (sensitivity 80%, specificity 83%, Q 2 =0.70). Alterations in the levels of different classes of lipids including triglycerides (TGs), phosphatidylinositols (PIs), phosphatidylcholines (PCs), phosphatidylethanolamines (PEs), free fatty acids, lysophospholipids and sphingolipids were observed in squamous carcinoma and adenocarcinoma lung cancer patients when compared with control patients. In conclusion, this study has identified candidate lipid biomarkers of non-small cell lung cancer patients which may be helpful to indicate the tumour subtype and to differentiate them from patients who do not have lung cancer. Measuring these biomarkers has the potential to improve diagnosis in patients with suspected lung cancer and risk stratification in screening.

show abstract

“…According to Wu et al (21) the mutation rate of the EGFR gene in women and men was 42.9 and 23.1%, respectively. In this study, the mutation rate in female patients was 68.42%, which was higher compared with that in male patients (37.5%), with a statistically significant difference (P<0.05) (10,18,19,21). The degree of differentiation of the tumor was an important index for assessing malignant potential and prognosis.…”

Section: Discussionmentioning

confidence: 53%

“…Tumor markers are mainly used in clinical practice to locate the primary tumor, screen high-risk populations, identify and diagnose benign and malignant tumors, determine tumor development, observe and evaluate the efficacy of tumor treatment and predict the (8)(9)(10). The number of studies investigating the association of tumor markers with the EGFR gene is currently limited.…”

Section: Introductionmentioning

confidence: 99%

Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China

Abdurahman

Anwar

Turghun

et al. 2015

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. This study was conducted to investigate the mutation status of epidermal growth factor receptor (EGFR) and its association with clinical characteristics and tumor markers in non-small-cell lung cancer (NSCLC) patients from the Xinjiang Uygur Autonomous Region in China. We enrolled 51 cases of NSCLC patients who received radical surgical treatment in the First Affiliated Hospital of Xinjiang Medical University. Quantitative polymerase chain reaction was applied to detect exons 18, 19, 20 and 21 of the EGFR gene in tumor tissues. Multiple tumor markers, including carcinoembryonic antigen (CEA), were assessed preoperatively. The EGFR-positive rate was 49.02% (25/51), with a mutation rate of 8% (2/25) in exon 18, 52% (13/51) in exon 19, 40% (10/51) in exon 21 and no mutations in exon 20. The positive mutation rate in men and women was 37.5% (12/32) and 68.42%, respectively (13/19), with a statistically significantly higher rate in women (P<0.05). There were also statistically significant differences among adenocarcinoma, adenosquamous carcinoma and squamous cell carcinoma cases (P<0.05), while no statistically significant differences were observed in adenocarcinoma cases regarding degree of differentiation, lymph node metastasis and TNM stage (P>0.05). There was a statistically significant association between the EGFR gene mutation status and the preoperative serum CEA level (P<0.05). The mutation rate of the EGFR gene was 68.42% in female lung adenocarcinoma patients, which supports the application of targeted therapy in such cases. However, whether it is possible to obtain information regarding targeted therapy through measuring the level of serum CEA for NSCLC patients with unknown EGFR mutation status requires further investigation through related studies including a higher number of cases. IntroductionLung cancer is one of the most common malignant tumors in humans, with an equally high incidence in men and in women. Approximately 80% of lung cancer cases are non-small-cell lung cancer (NSCLC) (1). The majority of the patients present with advanced-stage lung cancer at diagnosis, when radical excision is no longer feasible (2) and the remaining treatment options include radiotherapy, chemotherapy and immune therapy. The rate of response to radiotherapy and chemotherapy is only 15-35%, which may not effectively improve the survival rate and life quality of the patients. Therefore, the total 5-year survival rate of lung cancer patients is only ~15% (2-4).Over the last few years, genetic testing and targeted therapy based on epidermal growth factor receptor (EGFR) gene mutation status has attracted significant attention. Multiple clinical studies indicated that tyrosine kinase inhibitors (TKIs) have effectively extended the survival time and improved the life quality of NSCLC patients (5), with a total effectiveness rate of >70%. However, the effectiveness rate of TKI treatment for wild-type EGFR cancers is only 10-15% (6). Therefore, it is crucial to determine the mutation status of the EGFR gene in NSC...

show abstract

Serum Tumor Markers CEA, CYFRA21-1, and CA-125 Are Associated With Worse Prognosis In Advanced Non–Small-Cell Lung Cancer (NSCLC)

Cited by 182 publications

References 31 publications

Detection of cancer embryo antigen and endothelin-1 in exhaled breath condensate: A novel approach to investigate non-small cell lung cancer

Detection of cancer embryo antigen and endothelin-1 in exhaled breath condensate: A novel approach to investigate non-small cell lung cancer

Plasma lipid biomarker signatures in squamous carcinoma and adenocarcinoma lung cancer patients

Epidermal growth factor receptor gene mutation status and its association with clinical characteristics and tumor markers in non-small-cell lung cancer patients in Northwest China

Contact Info

Product

Resources

About